	US 12,460,204 B2
	Artificial nucleic acid molecules for improved protein or peptide expression
Andreas Thess, Kusterdingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Jul. 4, 2020, as Appl. No. 16/920,701.
Application 16/920,701 is a continuation of application No. 15/590,370, filed on May 9, 2017, granted, now 10,738,306.
Application 15/590,370 is a continuation of application No. 14/388,226, granted, now 9,683,233, issued on Jun. 20, 2017, previously published as PCT/EP2013/000937, filed on Mar. 27, 2013.
Claims priority of application No. PCT/EP2012/001336 (WO), filed on Mar. 27, 2012; and application No. PCT/EP2012/002447 (WO), filed on Jun. 8, 2012.
Prior Publication US 2020/0332293 A1, Oct. 22, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C12N 15/67 (2006.01); C12N 15/85 (2006.01)

CPC C12N 15/113 (2013.01) [A61K 39/00 (2013.01); A61K 48/0008 (2013.01); C12N 15/67 (2013.01); C12N 15/85 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 48/00 (2013.01); C12N 2310/531 (2013.01); C12N 2320/52 (2013.01); C12N 2840/105 (2013.01)]

33 Claims

1. An artificial nucleic acid molecule selected from the group consisting of

(i) a DNA molecule comprising, from 5′ to 3′:

a) at least one 5-untranslated region element (5′ UTR element) which comprises a nucleic acid sequence having an identity of at least 90% to the nucleic acid sequence according to SEQ ID NO: 1455; and

b) at least one open reading frame (ORF), wherein the ORF is heterologous relative to the 5′ UTR element; and

(ii) a RNA molecule encoded by the DNA molecule.